BUSINESS WIRE --Delivering another innovation for interventional cardiology, Medtronic, Inc. (NYSE: MDT - News), announced today the U.S. Food and Drug Administration (FDA) approval of the Integrity Coronary Stent System. The new platform for Medtronic’s coronary stents, including the Integrity bare-metal stent, is based on an advance in biomedical engineering called continuous sinusoid technology that enables the exploration of other breakthrough device concepts such as a polymer-free drug-filled stent.
